Semaglutide is typically recommended for individuals with a body mass index (BMI) of 30 or higher, or 27 and above for those with weight-related health conditions
According to research from the University of Southern California, demand for semaglutide, a popular GLP-1 drug, surged by 442% between January 2021 and December 2023, partly due to a reduction in the stigma associated with obesity treatment.
A wealth of information distilled into some great guidelines
If you still want to enjoy other shakes, add them during the day, but we do not recommend skipping the myGLP Lifestyle mix
Tirzepatide dose comparison with unit values At 10mg/mL, doses above 10mg require more than a single 100-unit syringe draw
[10] [11] However, balance efficacy against gastrointestinal tolerability, as adverse effects may compromise adherence